About Us
Rohto Advanced Research Hong Kong Limited (ARHK) was established in January 2019 by a Japanese company called Rohto Pharmaceutical Co., Ltd (ROHTO). The core businesses of ROHTO are pharmaceutical products including eye drops, cosmetics and functional foods. In research field, ROHTO specializes in developing cell culture techniques and as well as utilizing an aseptic automated system for manufacturing their products such as eye drops and cosmetics.
One of the main research areas ROHTO focuses on is regenerative medicine. In 2017, ROHTO started its first clinical trial using allogenic adipose-derived mesenchymal stromal cells against liver cirrhosis. In 2020, a clinical trial against severe COVID-19 pneumonia was also initiated, entering Phase II trials in 2021. Several more clinical trials are ongoing against various target indications in Japan. (Click here to find out more)
In accordance with the strategic planning and development of regenerative medicine and its related businesses, ARHK utilizes ROHTO’s expertise and cutting-edge technologies to contribute to the advancement of scientific research and people’s wellness.
ARHK is currently conducting scientific research on mesenchymal stromal cells in collaboration with multiple parties in Hong Kong, and worldwide.
As ARHK is celebrating our 3rd year anniversary in 2022, we aim to further expand our R&D activities worldwide, as well as looking forward to the discovery and encountering novel technologies.
